ft 08 nov 93 uk compani news genet engin promis celltech forthcom pound 180m flotat celltech biotechnolog compani today issu pathfind prospectu flotat valu group pound 180m compani rais pound 35m fund exist project new product enter develop slough base compani product readi market expect develop get 1996 earliest unlik emerg compani howev celltech abl slow rate cash resourc deplet research develop programm collabor larg pharmaceut compani fairli common practic contract manufactur monoclon antibodi notabl roch flotat take celltech ahead british bio technolog group term size among emerg drug discoveri develop busi leav smaller mani bio tech compani alreadi float matur us market celltech unusu root parentag found 1980 nation enterpris board medic research council develop technolog modifi structur antibodi protein produc bodi immun system alongsid research base celltech commercialis technolog laid foundat celltech biolog busi one world largest contract manufactur antibodi therapeut use way celltech also pick unusu sharehold form mr john gunn british amp commonwealth fail conglomer administr b amp c biggest seller among exist sharehold collect realis pound 35m float celltech promis product genet engin human antibodi cdp571 aim reduc septic shock life threaten condit lead rapidli fall blood pressur failur bodi organ bayer german compani advanc develop mous antibodi bay x1351 deal septic shock part collabor r amp allianc celltech exclus right ec countri market bayer product unusu arrang bayer exercis option licens celltech antibodi british compani retain substanti market right number european countri includ uk franc bayer paid second pound 4m mileston payment celltech octob privileg mr peter fellner celltech chief execut research director chief execut roch uk say link bayer unusu encourag result trial bayer result enhanc probabl septic shock product reach registr say bayer product third phase clinic trial larger phase iii studi gain regulatori approv launch us shortli celltech product would come onto market year bayer bayer exercis option would suggest expect celltech cdp571 product improv antibodi administ celltech product back develop pipelin includ treatment inflammatori bowel diseas also base cdp571 product antibodi treat acut myeloid leukaemia treatment rheumatoid arthriti like new drug develop compani celltech lack product profit make substanti riskier invest mani new flotat compani float us cover prospectu would carri promin amount seriou health warn us experi howev reward commensur larg biotechnolog compani success bring new drug market mr fellner argu justif risk celltech lower number reason compani cash burn rate modest last three year compani oper use pound 18 4m compar r amp invest pound 37m partli biolog posit cash flow year septemb 30 1993 increas oper profit fourfold pound 2m sale 15 per dent pound 14 2m r amp celltech loss year fell pound 7 5m pound 5 9m collabor also brought cash celltech alreadi receiv pound 8m pound 26m mileston payment bayer american cyanamid jointli develop antibodi base cancer therapi subscrib pound 3 5m prefer share roch celltech biolog manufactur seri antibodi subscrib pound 5m prefer share septemb result celltech emerg float cash pound 50m enough keep current project fulli fund substanti longer two year slow cash burn may reduc risk inher drug develop statist probabl programm fail produc drug effect other avail consider comfort investor look select portfolio emerg drug compani celltech unlik knock door fund strong new stori tell bare sponsor share issu cazenov broker